Drug General Information
Drug ID
D0TP9M
Former ID
DNCL002535
Drug Name
ACY-1215
Drug Type
Small molecular drug
Indication Autoimmune diabetes [ICD10:E08-E13] Phase 1/2 [524684], [542040]
Company
Acetylon Pharmaceuticals
Structure
Download
2D MOL

3D MOL

Formula
C24H27N5O3
InChI
InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
InChIKey
QGZYDVAGYRLSKP-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Histone deacetylase Target Info Modulator [544487]
Histone deacetylase 6 Target Info Modulator [544487]
KEGG Pathway Alcoholism
Viral carcinogenesis
Pathway Interaction Database Signaling events mediated by HDAC Class II
Signaling events mediated by HDAC Class I
Reactome NOTCH1 Intracellular Domain Regulates Transcription
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
Assembly of the primary cilium
WikiPathways Ectoderm Differentiation
Neural Crest Differentiation
Cell Cycle
References
Ref 524684ClinicalTrials.gov (NCT02091063) ACY-1215 for Relapsed/Refractory Lymphoid Malignancies. U.S. National Institutes of Health.
Ref 542040(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7010).
Ref 544487Promising therapies in multiple myeloma. Blood. 2015 July 16; 126(3): 300-310.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.